About Diarect
Diarect is a company based in Baden-baden (Germany) founded in 1998 by Bodo Liedvogel and Heinz Haubruck was acquired by BBI Group in June 2020. The company has 289 employees as of January 31, 2022. Diarect operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Baden-baden, Germany
- Employees 289 as on 31 Jan, 2022
- Founders Bodo Liedvogel, Heinz Haubruck
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bbi Solutions Oem Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$700.09 K (USD), Grant
Jul 01, 2016
-
Investors
European Union
& 1 more
-
Employee Count
289
as on Jan 31, 2022
-
Acquired by
BBI Group
(Jun 04, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Diarect
Investors in Diarect
Diarect has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and BBI Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Instruments and reagents are supplied for diagnostic and healthcare sectors.
|
Locked | Locked | Locked |
Investor details for Diarect
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diarect
Investment portfolio details for Diarect
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diarect
Detailed financials for Diarect
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diarect Comparisons
Peer comparison for Diarect
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diarect
Diarect operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Diarect
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diarect
Complete news archive for Diarect
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diarect
Diarect was founded in 1998 and raised its 1st funding round 18 years after it was founded.
Diarect is headquartered in Baden-baden, Germany. It is registered at Baden-baden, Baden-wurttemberg, Germany.
As of Jan 31, 2022, the latest employee count at Diarect is 289.
Diarect specializes in the development and production of recombinant and native antigens that are used in the development of immunoassays. The company manufactures a host of allergens (found in food, grasses and trees), a large collection of autoimmune disease antigens (including, SARD, Mixed Connective Tissue Disease, SLE, Sjøgrens Syndrome, Systemic Sclerosis CREST Syndrome, Polymyositis Dermatomyositis, Autoimmune Thyroid Diseases, Celiac Disease, Autoimmune Hepatitis, Primary Biliary Cirrhosis, ANCA-Associated Diseases, Antiphospholipid Syndrome Thromboembolic Syndrome, Anti-GBM Disease, Diabetes Mellitus, Pernicious Anemia, Crohns Disease), and infectious disease antigens (including Anaplasmosis, Babesiosis, Borreliosis Lyme Disease Relapsing Fever, Candidiasis, Erythema infectiosum, Scarlet Fever, Yersiniosis). The company is also the European distributor of SurModics protein stabilization reagents and blockers and BioFX substrates.
Diarect's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Diarect has 2 investors. Key investors include European Union, and BBI Group.